research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-04. Numbers and descriptions here follow the published literature rather than marketing material.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The Open Insulin Project is a community of researchers and advocates working to develop an open-source protocol for producing insulin that is affordable, has transparent pricing, and is community-owned.
Progesterone is used as a medication. The hormone is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels. It may also be used alone to treat menopausal symptoms. Studies have shown that transdermal progesterone (skin patch) and oral micronized progesterone are effective treatments for certain symptoms of menopause such as hot flashes and night sweats, otherwise referred to as vasomotor symptoms or VMS. Progesterone is also used to support pregnancy and fertility and to treat gynecological disorders. Progesterone has been shown to prevent miscarriage in those with vaginal bleeding early in their current pregnancy and having a previous history of miscarriage. Progesterone can be taken by mouth, through the vagina, and by injection into muscle or fat, among other routes.
Counterfeit Viagra, despite generally being cheaper, can contain harmful substances or substances that affect how Viagra works, such as blue printer ink, amphetamines, metronidazole, boric acid, and rat poison. Viagra is one of the world's most counterfeited medicines. According to a 2012 Pfizer study, around 80% of sites claiming to sell Viagra were selling counterfeits. An October 2023 release stated that erectile dysfunction medicines were the most seized drugs by the Interpol accounting for 22% of seizures. International networks may be active.
=== Health === DHIS2 is currently in use as a Health Management Information System in more than 75 low- and middle-income countries. 69 of these countries have deployed DHIS2 at national scale. DHIS2 is also used by national health authorities and international health programs and organizations for management of health programs related to specific diseases, such as HIV, TB, and Malaria, among others, as well as for general public health programs such as disease surveillance, routine immunization, and maternal and child health. In 2025, Bangladesh implemented an electronic health information system using the DHIS2 Tracker to manage and evaluate its national cervical screening program. In addition, during the COVID-19 pandemic, 55 countries rapidly deployed or extended DHIS2 for national pandemic response and/or vaccination.
Sources: en.wikipedia.org
== History and etymology == Discovered by Tillett and Francis in 1930, it was initially thought that CRP might be a pathogenic secretion since it was elevated in a variety of illnesses, including cancer. The later discovery of hepatic synthesis (made in the liver) demonstrated that it is a native protein. Initially, CRP was measured using the quellung reaction which gave a positive or a negative result. More precise methods nowadays use dynamic light scattering after reaction with CRP-specific antibodies. CRP was so named because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the cell wall polysaccharide (C-polysaccharide) of pneumococcus.
== Symbols and units == The IUPAC-recommended symbols for mass and charge are m and Q, respectively, however using a lowercase q for charge is also very common. Charge is a scalar property, meaning that it can be either positive (+) or negative (−). The Coulomb (C) is the SI unit of charge; however, other units can be used, such as expressing charge in terms of the elementary charge (e). The SI unit of the physical quantity m/Q is kilogram per coulomb.
== History == Migalastat was isolated as a fermentation product of the bacterium Streptomyces lydicus (strain PA-5726) in 1988 and called 1-deoxygalactonojirimycin. In 2004, it was designated orphan drug status by the U.S. FDA for the treatment of Fabry disease, as did the European Medicines Agency's CHMP in 2006. The sponsorship for the drug was transferred several times over the following years: from Amicus Therapeutics to Shire Pharmaceuticals in 2008, back to Amicus in 2010, to Glaxo in 2011, and again to Amicus in 2014. Two phase III clinical trials with a total of about 110 subjects were conducted between 2009 and 2015, one double-blind comparing the drug to placebo, and one comparing it to recombinant α-GalA without blinding. Migalastat stabilised heart and kidney function over the 30-months period of these trials. The efficacy of migalastat was demonstrated in a six-month, placebo-controlled clinical trial in 45 adults with Fabry disease. In this trial, participants treated with migalastat over six months had a greater reduction in globotriaosylceramide (GL-3) in blood vessels of the kidneys (as measured in kidney biopsy samples) as compared to participants on placebo. The safety of migalastat was studied in four clinical trials which included a total of 139 participants with Fabry disease. In September 2015, Amicus announced that it would submit a new drug application (NDA) for accelerated approval of migalastat to the FDA by the end of 2015.
Sources: en.wikipedia.org
At the Battle of Carabobo on 24 June, the Gran Colombian forces decisively defeated the royalist forces, assuring control of Venezuela save for Puerto Cabello and guaranteeing Venezuelan independence. Bolívar could now concentrate on Gran Colombia's claims to southern New Granada and Quito.
Pakistan's fauna mirrors its diverse climate. The country boasts around 668 bird species, including crows, sparrows, mynas, hawks, falcons, and eagles. Palas, Kohistan, is home to the western tragopan, with many migratory birds visiting from Europe, Central Asia, and India. The southern plains harbor mongooses, small Indian civet, hares, the Asiatic jackal, the Indian pangolin, the jungle cat, and the sand cat. Indus is home to mugger crocodiles, while surrounding areas host wild boars, deer, and porcupines. Central Pakistan's sandy scrublands shelter Asiatic jackals, striped hyenas, wildcats, and leopards. The mountainous north hosts a variety of animals like the Marco Polo sheep, urial, markhor goat, ibex goat, Asian black bear, and Himalayan brown bear. The lack of vegetative cover, severe climate, and grazing impact on deserts have endangered wild animals. The chinkara is the only animal found in significant numbers in Cholistan, with a few nilgai along the Pakistan–India border and in some parts of Cholistan. Rare animals include the snow leopard and the blind Indus river dolphin, of which there are believed to be about 1,816 remaining, protected at the Indus Dolphin Reserve in Sindh. In total, 174 species of mammals, 177 species of reptiles, 22 species of amphibians, 198 species of freshwater fish, 668 species of birds, over 5,000 species of insects, and over 5,700 species of plants have been recorded in Pakistan.
Pharmacology is the science of drugs and medications, including a substance's origin, composition and interaction with biological systems; specifically through pharmacokinetics, pharmacodynamics, therapeutic use, and toxicology. The discipline examines these interactions through pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body), both of which determine how a substance alters normal or abnormal biochemical function. Substances with medicinal properties are classified as pharmaceuticals, while the term drug encompasses any chemical agent that alters biological processes. Nanopharmacology is the specialization of pharmacology in the nanoscale. The field encompasses drug composition and properties, functions, sources, medicinal chemistry, drug design, molecular and cellular mechanisms, organ/systems mechanisms, signal transduction/cellular communication, molecular diagnostics, interactions, chemical biology, therapy, medical applications, toxicology, and antipathogenic capabilities. The two main areas of pharmacology are pharmacodynamics and pharmacokinetics. Pharmacodynamics studies the effects of a drug on biological systems, and pharmacokinetics studies the effects of biological systems on a drug. In broad terms, pharmacodynamics discusses the chemicals with biological receptors, and pharmacokinetics discusses the liberation, absorption, distribution, metabolism, and excretion (LADME) of chemicals from the biological systems. Pharmacology is not synonymous with pharmacy, though the two terms are frequently confused.
The Kozak consensus sequence (Kozak consensus or Kozak sequence) is a nucleic acid motif that functions as the protein translation initiation site in most transcripts of archaeal and eukaryotic mRNA. Archaeal transcriptomes use a mix of Kozak sequence, leaderless initiation and, more rarely, the Shine–Dalgarno sequence. Most of the initiation, elongation, and termination factors in archaea have homologs in eukaryotes. Regarded as the optimum sequence for initiating translation in eukaryotes, the sequence is an integral aspect of protein regulation and overall cellular health as well as having implications in human disease. It ensures that a protein is correctly translated from the genetic message, mediating ribosome assembly and translation initiation. A wrong start site can result in non-functional proteins. As it has become more studied, expansions of the nucleotide sequence, bases of importance, and notable exceptions have arisen. Haloarchaea are known to have a variant of the Kozak consensus sequence in their Hsp70 genes. The sequence was named after the scientist who discovered it, Marilyn Kozak. Kozak discovered the sequence through a detailed analysis of DNA genomic sequences. The Kozak sequence is not to be confused with the ribosomal binding site (RBS), that being either the 5′ cap of a messenger RNA or an internal ribosome entry site (IRES).
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.